Effect of TNF antagonists on the productivity of daily work of patients with rheumatoid arthritis

Journal of Multidisciplinary Healthcare

Volumn 6, Issue , 2013, Pages 25-30

  Furuya, Hidekazu ^a   Kasama, Tsuyoshi ^a   Isozaki, Takeo ^a,b   Umemura, Masayu ^a   Otsuka, Kumiko ^a   Isojima, Sakiko ^a   Tsukamoto, Hiroyuki ^a   Tokunaga, Takehiro ^a   Yanai, Ryo ^a   Takahashi, Ryo ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

DAS28; Etanercept; Infliximab; mHAQ; Productivity; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGED; ARTICLE; BIOLOGICAL THERAPY; CLINICAL ARTICLE; DISEASE ACTIVITY; FEMALE; HUMAN; IMMUNOASSAY; JAPAN; MALE; PHARMACOECONOMICS; RHEUMATOID ARTHRITIS; SCORING SYSTEM; VISUAL ANALOG SCALE; WORK DISABILITY; WORKLOAD;

EID: 84874717700     PISSN: None     EISSN: 11782390     Source Type: Journal    
DOI: 10.2147/JMDH.S39158     Document Type: Article

References (32)

1. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358: 903-911.
2. Jenkins JK, Hardy KJ, McMurray RW. The pathogenesis of rheumatoid arthritis: a guide to therapy. Am J Med Sci. 2002;323(4):171-180.
3. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376(9746):1094-1108.
4. Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LA, van Riel PL. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum. 2001;44(9):2009-2017.
5. Harriman G, Harper LK, Schaible TF. Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment. Ann Rheum Dis. 1999;58 Suppl 1:161-164.
6. Garrison L, McDonnell ND. Etanercept: therapeutic use in patients with rheumatoid arthritis. Ann Rheum Dis. 1999;58 Suppl 1:165-169.
7. Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum. 1984;27(8):864-872.
8. Yelin E, Henke C, Epstein W. The work dynamics of the person with rheumatoid arthritis. Arthritis Rheum. 1987;30(5):507-512.
9. Wolfe F, Hawley DJ. The longterm outcomes of rheumatoid arthritis: Work disability: a prospective 18 year study of 823 patients. J Rheumatol. 1998;25(11):2108-2117.
10. Strand V, Khanna D. The impact of rheumatoid arthritis and treatment on patients' lives. Clin Exp Rheumatol. 2010;28(3 Suppl 59):S32-S40.
11. Fautrel B, Woronoff-Lemsi MC, Ethgen M, et al. Impact of medical practices on the costs of management of rheumatoid arthritis by anti-TNFalpha biological therapy in France. Joint Bone Spine. 2005;72(6):550-556.
12. Laas K, Peltomaa R, Kautiainen H, Puolakka K, Leirisalo-Repo M. Pharmacoeconomic study of patients with chronic inflammatory joint disease before and during infliximab treatment. Ann Rheum Dis. 2006;65(7):924-928.
13. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-324.
14. van der Heijde DM, van 't Hof MA, van Riel PL, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis. 1990;49(11): 916-920.
15. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996;39(1):34-40.
16. Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum. 1983;26(11):1346-1353.
17. van der Heijde D, Han C, DeVlam K, et al. Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial. Arthritis Rheum. 2006;55(4):569-574.
18. Geuskens GA, Hazes JM, Barendregt PJ, Burdorf A. Predictors of sick leave and reduced productivity at work among persons with early inflammatory joint conditions. Scand J Work Environ Health. 2008;34(6):420-429.
19. Wolfe F, Allaire S, Michaud K. The prevalence and incidence of work disability in rheumatoid arthritis, and the effect of anti-tumor necrosis factor on work disability. J Rheumatol. 2007;34(11):2211-2217.
20. Smolen JS, Han C, van der Heijde D, et al. Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum. 2006;54(3):716-722.
21. Keat AC, Gaffney K, Gilbert AK, Harris C, Leeder J. Influence of biologic therapy on return to work in people with work disability due to ankylosing spondylitis. Rheumatology (Oxford). 2008;47(4):481-483.
22. Allaire S, Wolfe F, Niu J, Zhang Y, Zhang B, LaValley M. Evaluation of the effect of anti-tumor necrosis factor agent use on rheumatoid arthritis work disability: the jury is still out. Arthritis Rheum. 2008;59(8):1082-1089.
23. Bejarano V, Quinn M, Conaghan PG, et al. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum. 2008;59(10): 1467-1474.
24. Raterman HG, Hoving JL, Nurmohamed MT, et al. Work ability: a new outcome measure in rheumatoid arthritis? Scand J Rheumatol. 2010;39(2):127-131.
25. Kavanaugh A, Antoni C, Mease P, et al. Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis. J Rheumatol. 2006;33(11):2254-2259.
26. Yelin E, Meenan R, Nevitt M, Epstein W. Work disability in rheumatoid arthritis: effects of disease, social, and work factors. Ann Intern Med. 1980;93(4):551-556.
27. Karassa FB, Ioannidis JP, Touloumi G, Boki KA, Moutsopoulos HM. Risk factors for central nervous system involvement in systemic lupus erythematosus. QJM. 2000;93(3):169-174.
28. Rat AC, Boissier MC. Rheumatoid arthritis: direct and indirect costs. Joint Bone Spine. 2004;71(6):518-524.
29. Yelin E. The costs of rheumatoid arthritis: absolute, incremental, and marginal estimates. J Rheumatol Suppl. 1996;44:47-51.
30. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353-365.
31. Reilly MC, Gooch KL, Wong RL, Kupper H, van der Heijde D. Validity, reliability and responsiveness of the Work Productivity and Activity Impairment Questionnaire in ankylosing spondylitis. Rheumatology (Oxford). 2010;49(4):812-819.
32. Zhang W, Bansback N, Boonen A, Young A, Singh A, Anis AH. Validity of the work productivity and activity impairment questionnaire-general health version in patients with rheumatoid arthritis. Arthritis Res Ther. 2010;12(5):R177.